NCT07730177 PfSPZ-LARC2 Vaccine(Sanaria) Malaria, Falciparum Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07730177 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.

MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.

Why NCT07730177 is a hot trial to watch

Malaria, Falciparum is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07730177 is notable because it evaluates PfSPZ-LARC2 Vaccine(Sanaria) in a Phase 1 design sponsored by Sanaria, Inc.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.

Trial landscape snapshot

Protocol design and endpoint interpretation

This is a randomized, double-blind, placebo-controlled, Phase 1 trial of Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) malaria vaccine (Sanaria® PfSPZ-LARC2 Vaccine) administered to healthy, malaria-exposed adults by direct venous inoculation (DVI) to determine safety, immunogenicity, and efficacy against controlled human malaria infection (CHMI). The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double deletion of the genes encoding the Mei2 and LINUP proteins, both of which are required for transition from liver to blood stage malaria. As a result, mei2-/linup- parasites undergo developmental arrest in the late liver stages without releasing merozoites into the blood stream. No blood stage parasites are produced, either asexual or sexual, and the parasite life cycle does not progress. CHMI will be performed using PfSPZ Challenge (NF54), composed of PfSPZ that are genetically intac

Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment. Planned enrollment of [object Object] participants across Burkina Faso shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Efficacy of PfSPZ-LARC2 Vaccine against infection with Plasmodium falciparum malaria (defined as asexual parasitemia) after Controlled Human Malaria Infection (CHMI) (Study day 43 (day of CHMI) to Study day 71 (28 days after CHMI)) — Frequency of P. falciparum asexual parasitemia in each vaccine group relative to controls after controlled human malaria infection (CHMI). Participants will be followed as outpatients for malaria diagnosis, treatment, and follow-up for four weeks after CHMI until day CHMI+28. Malaria positivity will be determined in real time by TBS microscopy read immediately and with qPCR diagnostics based on concurrent DBS complet
• Safety and tolerability of PfSPZ-LARC2 Vaccine administration in malaria-exposed Burkinabe adults- grade 3 solicited AEs (Study day 1 (day of immunization) to study day 15) — Incidence of grade 3 solicited adverse events (AEs) in the 14 days after PfSPZ-LARC2 Vaccine administration
• Safety and tolerability of PfSPZ-LARC2 Vaccine administration in malaria-exposed Burkinabe adults- grade 3 unsolicited AEs (study day 1 (day of immunization) to study day 29) — Incidence of grade 3 unsolicited AEs in the 28 days after PfSPZ-LARC2 Vaccine administration
• Safety and tolerability of PfSPZ-LARC2 Vaccine administration in malaria-exposed Burkinabe adults- grade 3 laboratory AEs (study day 1 (day of immunization) to study day 8) — Incidence of grade 3 abnormal laboratory values one week after PfSPZ-LARC2 Vaccine administration

Readout outlook and evidence gap

The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.

Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset MCP profile: PfSPZ-LARC2 Vaccine(Sanaria) is indexed as Live attenuated vaccine, Prophylactic vaccine, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status Phase 2.

Company & Deal Intelligence MCP profile: Sanaria, Inc. is resolved to a normalized organization record in MONTGOMERY COUNTY, United States. The organization workflow adds identity, location, portfolio and partnering context where available.

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.

Bottom line

NCT07730177 provides a focused lens on Malaria, Falciparum development. Its value will be determined by whether PfSPZ-LARC2 Vaccine(Sanaria) can convert the current Phase 1 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.